[go: up one dir, main page]

GB2327675B - Nicotinamide derivatives and their use as medicaments - Google Patents

Nicotinamide derivatives and their use as medicaments

Info

Publication number
GB2327675B
GB2327675B GB9816099A GB9816099A GB2327675B GB 2327675 B GB2327675 B GB 2327675B GB 9816099 A GB9816099 A GB 9816099A GB 9816099 A GB9816099 A GB 9816099A GB 2327675 B GB2327675 B GB 2327675B
Authority
GB
United Kingdom
Prior art keywords
medicaments
nicotinamide derivatives
nicotinamide
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB9816099A
Other versions
GB2327675A (en
GB9816099D0 (en
GB2327675A8 (en
Inventor
Akiharu Kajiwara
Satoshi Nagato
Joanna Elizabeth Brashaw
Mary Louise Morgan
James Martin Staddon
Lee Laurence Rubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of GB9816099D0 publication Critical patent/GB9816099D0/en
Publication of GB2327675A publication Critical patent/GB2327675A/en
Publication of GB2327675A8 publication Critical patent/GB2327675A8/en
Application granted granted Critical
Publication of GB2327675B publication Critical patent/GB2327675B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB9816099A 1997-07-23 1998-07-23 Nicotinamide derivatives and their use as medicaments Expired - Fee Related GB2327675B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9715584.0A GB9715584D0 (en) 1997-07-23 1997-07-23 Compounds

Publications (4)

Publication Number Publication Date
GB9816099D0 GB9816099D0 (en) 1998-09-23
GB2327675A GB2327675A (en) 1999-02-03
GB2327675A8 GB2327675A8 (en) 1999-02-25
GB2327675B true GB2327675B (en) 2002-04-24

Family

ID=10816363

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB9715584.0A Pending GB9715584D0 (en) 1997-07-23 1997-07-23 Compounds
GB9816099A Expired - Fee Related GB2327675B (en) 1997-07-23 1998-07-23 Nicotinamide derivatives and their use as medicaments

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB9715584.0A Pending GB9715584D0 (en) 1997-07-23 1997-07-23 Compounds

Country Status (2)

Country Link
JP (1) JP3987645B2 (en)
GB (2) GB9715584D0 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
NZ526531A (en) 2001-01-31 2005-02-25 Pfizer Prod Inc Ether derivatives useful as inhibitors of phosphodiesterase type IV (PDE4) isozymes
EA200300621A1 (en) 2001-01-31 2003-12-25 Пфайзер Продактс Инк. BIARRYLIC DERIVATIVES OF NICOTINAMIDE, USEFUL AS AN INHIBITORS OF PDE4 ISOERMINENTS
PL365443A1 (en) 2001-01-31 2005-01-10 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
GB0317472D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as PDE4 inhibitors
US8597947B2 (en) 2004-12-29 2013-12-03 Hadasit Medical Research Services & Development Limited Undifferentiated stem cell culture systems
WO2006070370A2 (en) 2004-12-29 2006-07-06 Hadasit Medical Research Services & Development Limited Stem cells culture systems
US20100056791A1 (en) 2006-09-01 2010-03-04 Yasushi Kohno Pyrazolopyridine carboxamide derivative and phosphodiesterase (pde) inhibitor containing the same
EP2147094B2 (en) 2007-04-18 2018-02-21 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
ES2552733T3 (en) 2007-11-16 2015-12-01 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
WO2009076631A1 (en) 2007-12-12 2009-06-18 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
FR2926297B1 (en) 2008-01-10 2013-03-08 Centre Nat Rech Scient INHIBITORY CHEMICAL MOLECULES IN THE SPLICE MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICE ANOMALIES.
WO2009132136A1 (en) 2008-04-23 2009-10-29 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
EP2505198A1 (en) 2011-04-01 2012-10-03 Société Splicos Compounds for use as therapeutic agents affecting p53 expression and/or activity
KR101412794B1 (en) * 2011-07-27 2014-07-01 보령제약 주식회사 New compound, the preparation thereof and the pharmaceutical composition comprising the same for anti-angiogenic drug
SG11201705379VA (en) 2014-12-30 2017-08-30 Cell Cure Neurosciences Ltd Rpe cell populations and methods of generating same
ES2880346T3 (en) 2014-12-30 2021-11-24 Cell Cure Neurosciences Ltd Evaluation of retinal pigment epithelial cell populations
EP3862425A1 (en) 2015-07-29 2021-08-11 Hadasit Medical Research Services and Development Ltd. Large scale production of retinal pigment epithelial cells
JP6868608B2 (en) 2015-08-05 2021-05-12 セル キュア ニューロサイエンシズ リミテッド Preparation of photoreceptors for the treatment of retinal diseases
DK3331994T3 (en) 2015-08-05 2022-11-21 Cell Cure Neurosciences Ltd PRODUCTION OF RETINAL PIGMENT EPITHELIAL CELLS
JP6987769B2 (en) 2015-10-26 2022-01-05 セル キュア ニューロサイエンシズ リミテッド Preparation method of retinal pigment epithelial cells
CN110913874A (en) 2017-03-16 2020-03-24 谱系细胞疗法公司 Method for measuring the efficacy of a retinal disease therapy
BR112020013238A2 (en) 2017-12-29 2020-12-01 Cell Cure Neurosciences Ltd. composition and method for formulating retinal pigment epithelial cells as well as the use of said composition to treat a retinal condition
WO2020058979A2 (en) 2018-09-20 2020-03-26 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral sclerosis
WO2022261320A1 (en) 2021-06-09 2022-12-15 Lineage Cell Therapeutics, Inc. Methods and compositions for treating retinal diseases and conditions
CN117957311A (en) 2021-07-28 2024-04-30 谱系细胞疗法公司 Expansion of retinal pigment epithelial cells
WO2023211857A1 (en) 2022-04-25 2023-11-02 Lineage Cell Therapeutics, Inc. Methods and compositions for treating vision loss

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5082075A (en) * 1973-11-20 1975-07-03
JPH01113369A (en) * 1987-10-23 1989-05-02 Mitsubishi Petrochem Co Ltd Nicotinic acid amide compounds
US4861891A (en) * 1988-08-31 1989-08-29 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
EP0767172A1 (en) * 1995-10-06 1997-04-09 Boehringer Ingelheim Pharmaceuticals Inc. 8-Arylalkyl- and 8-arylheteroalkyl-5, 11-dihydro-6H-dipyrido-[3,2-b:2', 3'-e][1,4]diazepines and their use in the prevention or treatment of HIV infection
EP0773024A2 (en) * 1995-10-27 1997-05-14 Pfizer Inc. Use of N-substituted nicotinamide compounds for the treatment of acute and chronic inflammatory diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5082075A (en) * 1973-11-20 1975-07-03
JPH01113369A (en) * 1987-10-23 1989-05-02 Mitsubishi Petrochem Co Ltd Nicotinic acid amide compounds
US4861891A (en) * 1988-08-31 1989-08-29 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
EP0357316A1 (en) * 1988-08-31 1990-03-07 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
EP0767172A1 (en) * 1995-10-06 1997-04-09 Boehringer Ingelheim Pharmaceuticals Inc. 8-Arylalkyl- and 8-arylheteroalkyl-5, 11-dihydro-6H-dipyrido-[3,2-b:2', 3'-e][1,4]diazepines and their use in the prevention or treatment of HIV infection
EP0773024A2 (en) * 1995-10-27 1997-05-14 Pfizer Inc. Use of N-substituted nicotinamide compounds for the treatment of acute and chronic inflammatory diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Chem. Abs. 111:153648 & JP01113369 A2.(MITSUBISHI PETROCHEM-ICAL CO.) *
Chem. Abs. 120:217217 & Khim.-Farm. Zh. (1993), 27(7), 34-5 *
Chem. Pharm. Bull.(1997),45(6),1027-1038 *
Chemical Abstracts 125:247619 and WO97/32854A1 *
J. Med. Chem.(1995),38(24),4830-8 *

Also Published As

Publication number Publication date
GB2327675A (en) 1999-02-03
GB9816099D0 (en) 1998-09-23
GB2327675A8 (en) 1999-02-25
GB9715584D0 (en) 1997-10-01
JPH11147874A (en) 1999-06-02
JP3987645B2 (en) 2007-10-10

Similar Documents

Publication Publication Date Title
GB2327675B (en) Nicotinamide derivatives and their use as medicaments
HUP0001243A3 (en) Nicotinamide derivatives and pharmaceutical compositions containing them
IL144637A0 (en) Diaryl derivatives and their use as medicaments
HU9800743D0 (en) Dithiolan derivatives, their preparation and their therapeutic effect
IL130297A0 (en) Sulphonamide derivatives process for their preparation and their use as medicaments
NZ321576A (en) 6-imidazol-1-ylmethyl-2-oxo-quinoline derivatives and medicaments
NZ281404A (en) Tricyclic pyrimidine derivatives and medicaments
ZA989505B (en) Substituted isoquinoline-3-carboxamides their preparation and their use as pharmaceuticals
HUP0101099A3 (en) Substituted pyridine and pyridazine compounds and their pharmaceutical use
EP1024130A4 (en) Biphenyl-5-alkanoic acid derivatives and use thereof
HUP0102585A3 (en) Thienylazolylalcoxyethanamin derivatives preparation the same and their use as medicaments
LT2000004A (en) Derivatives of acyl-piperazinil-pyrimidins, preparation thereof and application as medicaments
AU6721598A (en) Dioxino derivatives and their use as therapeutic agents
NZ332309A (en) Alkylamino-benzothiazole and -benzoxazole derivatives and medicaments
AU5161399A (en) N-benzocycloalkyl-amide derivatives and their use as medicaments
IL116525A0 (en) Piperazinedione derivatives their preparation and use
ZA989556B (en) Benzoxazine derivatives their preparation and their therapeutic application
HUP9802807A3 (en) 1,3,8-triazo-spiro[4,5]decan-4-on derivatives, their use, production thereof and medicaments containing the same
HU0001396D0 (en) 3-amino-3-arylpropan-1-al derivatives and their use
ZA952410B (en) Substituted heterocyclic carboxamioesters their preparation and their use as pharmaceuticals
HK1036273A1 (en) Pyridine derivative and pharmaceutical containing the same
HUP9802590A3 (en) Indan-, benzothiophene-, benzofuran- and indolesulfonamide derivatives, their use and pharmaceutical compositions containing them
IL123535A0 (en) Benzoxazindione derivatives and their use
AU6520198A (en) Quinolinomorphinane derivatives and medicinal use thereof
GB2324090B (en) 5,6-O-alkylidene glucono-1(4)-lactones and derivatives thereof,their preparation and use

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20110723